SCHEMBL355010

SCHEMBL355010

Cc1nsc(-c2ccc(N3CCN(C(=O)OC(C)(C)C)CC3)c(F)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY2R P49146 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 4/20 0.43
SMPD3 Q9NY59 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
GPR119 Q8TDV5 3/20 0.42
LMNA P02545 2/20 0.41
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TACR3 P29371 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354865 0.80 GPR119 (0.55) NPY2RL3MBTL1MAPTSMPD3MEN1
SCHEMBL8221031 0.78 GPR119 (0.56) NPY2RL3MBTL1MAPTGPR119LMNA
SCHEMBL3929365 0.78 L3MBTL1 (0.55) L3MBTL1MAPTMEN1KMT2AGPR119
SCHEMBL22532774 0.76 SMN1; SMN2 (0.56) L3MBTL1MAPTMEN1KMT2AGPR119
SCHEMBL4951947 0.75 ESR2 (0.52) L3MBTL1MAPTMEN1KMT2AGPR119
SCHEMBL30221986 0.75 ESR2 (0.52) L3MBTL1MAPTMEN1KMT2AGPR119
SCHEMBL356667 0.75 L3MBTL1 (0.43) L3MBTL1MAPTSMPD3MEN1KMT2A
SCHEMBL660403 0.74 NR1H2 (0.53) L3MBTL1MAPTMEN1KMT2AGPR119
SCHEMBL1907784 0.74 CYP3A4 (0.56) L3MBTL1MAPTMEN1KMT2AGPR119
SCHEMBL7123953 0.74 BACE1 (0.54) L3MBTL1MAPTMEN1KMT2AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015957-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2012-01-19 US disclosed
WO-2009079593-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015957-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR NPY2R, NPY1R, NPY5R NPY2R 1/4885L3MBTL1 4722/4885MAPT 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.